BiomeOne
determines the probability of response to immune checkpoint inhibitor therapy (anti-CTLA-4, anti-PD-1 or anti-PD-L1). The analysis is based on a single stool sample in which the bacterial composition in the intestine is determined. The results are evaluated with the help of artificial intelligence. In that way the treating medical professionals learn whether a patient will respond to a therapy and whether side effects will occur.
